You are here

SignalRx Pharmaceuticals Inc.

Company Information
Address
12545 El Camino Real Unit C
San Diego, CA 92130-4051
United States


http://www.signalrx.com

Information

DUNS: 078516096

# of Employees: 2


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Overcoming BTK inhibitor resistance in B-cell malignancies

    Amount: $299,888.00

    Covalent inhibition of Bruton s tyrosine kinaseBTKis a clinically validated mechanism for treating B cell malignancies as illustrated by the FDA approval of ibrutinibIin mantle cell lymphomaMCLinand a ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  2. Discovery of novel CDK4/6-PI3K-BRD4 inhibitor SRX3177 for augmented anti-cancer activity

    Amount: $299,738.00

    Three CDKinhibitors were recently approved to treat breast cancerBrCAin combination regimentsDespite significant clinical activitytreatment of BrCA patients with these combinations does not result in ...

    STTRPhase I2018Department of Health and Human Services National Institutes of Health
  3. Development of the first-in-class novel dual PI-3K/BRD4 inhibitor SF2523

    Amount: $1,968,269.00

    There is an unmet need to inhibit the key cancer promoting transcription factor MYCboth c MYC and MYCNthat act downstream of many cell receptors and signal transcription pathways to activate genes for ...

    STTRPhase II2017Department of Health and Human Services National Institutes of Health
  4. Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors

    Amount: $299,738.00

    PARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to devel ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  5. Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors

    Amount: $209,001.00

    DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and s ...

    STTRPhase I2015Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government